Literature DB >> 27387224

Prevalence and emergence of carbapenemases-producing Gram-negative bacteria in Mediterranean basin.

Najla Mathlouthi1,2,3, Charbel Al-Bayssari2, Sofiane Bakour2, Jean Marc Rolain2, Chedly Chouchani1,3.   

Abstract

The emergence and the global spread of carbapenemases concern to health services worldwide. Their celestial rise among Gram-negative bacilli has challenged both the scientific and pharmaceutical sectors. Indeed, infections caused by these bacteria have limited treatment options and have been associated with high mortality and morbidity rates. Carbapenemase producers are mainly identified among Klebsiella pneumoniae, Escherichia coli, Pseudomonas aeruginosa, and Acinetobacter baumannii and still mostly in hospital settings and rarely in the community. They are closely related to KPC, VIM, IMP, NDM, and OXA-48 types. The encoding genes are mostly plasmid located and associated with various mobile genetic elements. The Mediterranean area is of interest due to a great diversity and population mixing. The prevalence of carbapenemases is particularly high and variant among countries, partially depending on the population exchange relationship between the regions and the possible reservoirs of each carbapenemase. This review described the epidemiology of carbapenemases in this region of the world highlighting the worrisome situation and the need to screen and detect these enzymes to prevent and control their dissemination especially as it is clear that very few novel antibiotics will be introduced in the next few years, making the dissemination of carbapenem-resistant Gram-negative bacteria of crucial importance worldwide.

Entities:  

Keywords:  Carbapenemases; Gram-negative bacteria; Mediterranean countries

Mesh:

Substances:

Year:  2016        PMID: 27387224     DOI: 10.3109/1040841X.2016.1160867

Source DB:  PubMed          Journal:  Crit Rev Microbiol        ISSN: 1040-841X            Impact factor:   7.624


  6 in total

1.  Tracking Multidrug-Resistant Klebsiella pneumoniae from an Italian Hospital: Molecular Epidemiology and Surveillance by PFGE, RAPD and PCR-Based Resistance Genes Prevalence.

Authors:  Giancarlo Ripabelli; Manuela Tamburro; Giuliana Guerrizio; Incoronata Fanelli; Romeo Flocco; Massimiliano Scutellà; Michela L Sammarco
Journal:  Curr Microbiol       Date:  2018-03-09       Impact factor: 2.188

2.  Dissemination of Carbapenemases (OXA-48, NDM and VIM) Producing Enterobacteriaceae Isolated from the Mohamed VI University Hospital in Marrakech, Morocco.

Authors:  Souad Loqman; Nabila Soraa; Seydina M Diene; Jean-Marc Rolain
Journal:  Antibiotics (Basel)       Date:  2021-04-26

3.  VIM-1 carbapenemase-producing Escherichia coli in gulls from southern France.

Authors:  Marion Vittecoq; Chrislène Laurens; Lionel Brazier; Patrick Durand; Eric Elguero; Audrey Arnal; Frédéric Thomas; Salim Aberkane; Nicolas Renaud; Franck Prugnolle; Jérôme Solassol; Hélène Jean-Pierre; Sylvain Godreuil; François Renaud
Journal:  Ecol Evol       Date:  2017-01-25       Impact factor: 2.912

4.  Molecular characterization of carbapenem-resistant Gram-negative bacilli clinical isolates in Algeria.

Authors:  Nadjette Bourafa; Wafaa Chaalal; Sofiane Bakour; Rym Lalaoui; Nafissa Boutefnouchet; Seydina M Diene; Jean-Marc Rolain
Journal:  Infect Drug Resist       Date:  2018-05-17       Impact factor: 4.003

5.  Use of Next Generation Sequencing and Synergy Susceptibility Testing in Diagnosis and Treatment of Carbapenem-Resistant Klebsiella pneumoniae Blood Stream Infection.

Authors:  Yuetian Yu; Fupin Hu; Cheng Zhu; Erzhen Chen; Liangjing Lu; Yuan Gao
Journal:  Case Rep Infect Dis       Date:  2018-01-23

6.  Inhibitory Potential of Polyclonal Camel Antibodies against New Delhi Metallo-β-lactamase-1 (NDM-1).

Authors:  Rahma Ben Abderrazek; Sarra Chammam; Ayoub Ksouri; Mariagrazia Perilli; Sayda Dhaouadi; Ines Mdini; Zakaria Benlasfar; Gianfranco Amicosante; Balkiss Bouhaouala-Zahar; Alessandra Piccirilli
Journal:  Molecules       Date:  2020-09-28       Impact factor: 4.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.